Abstract
Background: Most experimental studies of chronic ciclosporin A (CsA) nephrotoxicity have been performed in rodents; however, the pig possesses several advantages. The aim of this study was to investigate renal functional and structural changes during CsA treatment with 20 mg/kg/day for 6 months in a pig model. Methods: Göttingen minipigs were randomized to oral CsA treatment or as controls. At 0, 5, 10, 15, 20 and 25 weeks body weight, blood pressure, serum creatinine, and whole blood CsA levels were measured. Magnetic resonance imaging was used to estimate relative glomerular filtration rate (rGFR), renal blood flow (RBF), kidney length and volume. Renal vascular resistance (RVR) was calculated. Kidney tissue biopsies were taken and volume fraction of cortical interstitial tissue estimated by a stereology-based method. Results: CsA induced significant increases in serum creatinine, blood pressure, RVR, and a significant decrease in RBF. Furthermore, renal volume increased significantly. This finding was inversely related to the decrease in RBF and initially followed by an increase in rGFR, which then decreased. No significant histopathological kidney changes were observed. Conclusion: CsA treatment with 20 mg/kg/day for 6 months causes increased serum creatinine, blood pressure, RVR, and renal volume along with a decrease in RBF in accordance with data obtained in humans. The initial temporal changes in renal volume and function during CsA administration have similarities to the functional changes seen in early diabetes.
Journal Section:
Original Paper
References
1.
Bennett WM, DeMattos A, Meyer MM, Andoh T, Barry JM: Chronic cyclosporine nephropathy: the Achilles’ heel of immunosuppressive therapy. Kidney Int 1996;50:1089–1100.
[PubMed]
2.
Falkenhain ME, Cosio FG, Sedmak DD: Progressive histologic injury in kidneys from heart and liver transplant recipients receiving cyclosporine. Transplantation 1996;62:364–370.
[PubMed]
3.
Fioretto P, Steffes MW, Mihatsch MJ, Strom EH, Sutherland DE, Mauer M: Cyclosporine associated lesions in native kidneys of diabetic pancreas transplant recipients. Kidney Int 1995;48:489–495.
[PubMed]
4.
Zachariae H, Kragballe K, Hansen HE, Marcussen N, Olsen S: Renal biopsy findings in long-term cyclosporin treatment of psoriasis. Br J Dermatol 1997;136:531–535.
[PubMed]
5.
Kopp JB, Klotman PE: Cellular and molecular mechanisms of cyclosporin nephrotoxicity. J Am Soc Nephrol 1990;1:162–179.
[PubMed]
6.
Ruiz P, Kolbeck PC, Scroggs MW, Sanfilippo F: Associations between cyclosporine therapy and interstitial fibrosis in renal allograft biopsies. Transplantation 1988;45:91–95.
[PubMed]
7.
Rosen S, Greenfeld Z, Brezis M: Chronic cyclosporine-induced nephropathy in the rat. A medullary ray and inner stripe injury. Transplantation 1990;49:445–452.
[PubMed]
8.
Elzinga LW, Rosen S, Bennett WM: Dissociation of glomerular filtration rate from tubulointerstitial fibrosis in experimental chronic cyclosporine nephropathy: Role of sodium intake. J Am Soc Nephrol 1993;4:214–221.
[PubMed]
9.
Terris JM: Swine as a model in renal physiology and nephrology: an overview; in Tumbleson ME (3rd ed): Swine in Biomedical Research. New York, Plenum Press, 1986, pp 1673–1689.
10.
Cibulskyte D, Kaalund H, Pedersen M, Hørlyck A, Marcussen N, Hansen HE, et al: Chronic cyclosporine nephrotoxicity: a pig model. Transplant Proc 2005;37:3298–3301.
[PubMed]
11.
Frey BM, Sieber M, Mettler D, Ganger H, Frey FJ: Marked interspecies differences between humans and pigs in cyclosporine and prednisolone disposition. Drug Metab Dispos 1988;16:285–289.
[PubMed]
12.
Grøn MC, Kristensen DH, Cibulskyte D, Hørlyck A, Kaalund H, Hansen HE, et al: Changes in renal dimensions evaluated by magnetic resonance imaging and ultrasonography during long-term ciclosporin-A treatment. Acta Radiol 2006;47:58–64.
[PubMed]
13.
Cibulskyte D, Pedersen M, Hjelm-Poulsen J, Hansen HE, Madsen M, Mortensen J: The pharmacokinetics and acute renal effects of oral microemulsion ciclosporin A in normal pigs. Int Immunopharmacol 2006;6:627–634.
[PubMed]
14.
Cheung CM, Shurrab AE, Buckley DL, Hegarty J, Middleton RJ, Mamtora H, Kalra PA: MR-derived renal morphology and renal function in patients with atherosclerotic renovascular disease. Kidney Int 2006;69:715–722.
[PubMed]
15.
El-Diasty TA, El-Ghar ME, Shokeir AA, Gad HM, Wafa EW, El-Azab ME, et al: Magnetic resonance imaging as a sole method for the morphological and functional evaluation of live kidney donors. BJU Int 2005;96:111–116.
[PubMed]
16.
Ringgaard S, Christiansen T, Bak M, Pedersen EM, Stødkilde-Jørgensen H, Flyvbjerg A: Measurement of renal vein blood flow in rats by high-field magnetic resonance. Kidney Int 1997;52:1359–1363.
[PubMed]
17.
Ellingsen AR, Nyengaard JR, Østerby R, Jørgensen KA, Petersen SE, Marcussen N: Measurements of cortical interstitium in biopsies from human kidney grafts: How representative and how reproducible? Nephrol Dial Transplant 2002;17:788–792.
[PubMed]
18.
Vaden SL, Riviere JE: Pharmacokinetics, inhibition of lymphoblast transformation, and toxicity of cyclosporine in clinically normal pigs. Am J Vet Res 1990;51:399–403.
[PubMed]
19.
Dean SK, Scott H, Keogh GW, Roberts S, Tuch BE: Effect of immunosuppressive doses of cyclosporine on pancreatic beta cell function in pigs. Am J Vet Res 2002;63:1501–1506.
[PubMed]
20.
Dieperink H, Leyssac PP, Starklint H, Kemp E: Long-term cyclosporin nephrotoxicity in the rat: effects on renal function and morphology. Nephrol Dial Transplant 1988;3:317–326.
[PubMed]
21.
Saad SY, Najjar TA: Effects of STZ-induced diabetes and its treatment with vanadyl sulphate on cyclosporine A-induced nephrotoxicity in rats. Arch Toxicol 2005;79:493–499.
[PubMed]
22.
Bak M, Thomsen K, Christiansen T, Flyvbjerg A: Renal enlargement precedes renal hyperfiltration in early experimental diabetes in rats. J Am Soc Nephrol 2000;11:1287–1292.
[PubMed]
23.
Hansen HE, Skov PE, Hansen HH, Taagehoj-Jensen F: Radioisotope renography, glomerular filtration rate and effective renal plasma flow in donors with normal renal function after nephrectomy. Acta Med Scand 1974;195:359–363.
[PubMed]
© 2007 S. Karger AG, Basel
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
2007
You do not currently have access to this content.
